Observational studyCancer imaging : the official publication of the International Cancer Imaging Society2026
Apparent diffusion coefficient and kurtosis parameters show early response to anti-angiogenic therapy in patients with colorectal liver metastases.
Observational study in Cancer imaging : the official publication of the International Cancer Imaging Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03010722 (A Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy in RAS Mutant Metastatic Colorectal Cancer), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Prospective Translational Study Investigating Molecular Predictors of Resistance and Response to Regorafenib Monotherapy in RAS Mutant Metastatic Colorectal Cancer
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundTo investigate whether the diffusion kurtosis imaging (DKI) technique can identify tumour response to an anti-angiogenic therapy in a pilot study of patients with RAS-mutant colorectal liver metastases.
methodsThis prospective imaging study enrolled 20 participants receiving Regorafenib treatment. A target metastasis > 2 cm in each patient was imaged before and at 15 days after treatment on a 1.5T MR scanner using a coronal, free-breathing DKI protocol. Data were motion-corrected and modelled using both the mono-exponential and DKI models. Median values derived from voxel-wise analysis of the whole delineated tumour were reported for three parameters [apparent diffusion coefficient (ADC, 10
resultsSignificant treatment-induced changes across the cohort were observed for all parameters: K decrease (0.907 vs. 0.786, P < 0.01; 13.3%), D increase (1.256 vs. 1.386 × 10
conclusionsBoth ADC and DKI parameters showed a significant early cohort change to the anti-angiogenic effects of Regorafenib treatment in RAS-mutant colorectal liver metastases. The ADC parameter performed better than the K parameter in identifying patients benefitting from the treatment.
trial registrationNCT03010722 clinicaltrials.gov; registration date 6
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.